LINCOLNSHIRE, Ill., December 01, 2025--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the launch of Tacrolimus Injection, USP 5 mg/mL. This launch signifies the first and only Tacrolimus ...
Tacrolimus 5mg/mL; soln for IV infusion after dilution; contains polyoxyl 60 hydrogenated castor oil. Give at least 6hrs after transplantation if unable to tolerate oral caps. Heart: initially ...
Austin, April 23, 2026 (GLOBE NEWSWIRE)-- According to SNS Insider, The Tacrolimus Market size is valued at USD 7.34 Billion in 2025 and is projected to reach USD 12.08 Billion by 2035, growing at a ...
SEATTLE, June 17, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global tacrolimus market is estimated to be valued at US$ 6,485.3 million in 2022 and is expected to exhibit a CAGR of ...
Rising Organ Transplants and Autoimmune Cases Propel Tacrolimus Market Growth; Innovation and Hospital Reliance Boost Adoption Tacrolimus Market Tacrolimus Market Dublin, May 25, 2026 (GLOBE NEWSWIRE) ...
Tacrolimus Injection is a crucial immunosuppressant indicated for the prophylaxis of organ rejection in patients receiving liver or kidney transplants. “We are pleased to share the launch of Nexus’ ...
Nexus Pharmaceuticals, LLC announces the launch of Tacrolimus Injection, USP 5 mg/mL. This launch signifies the first and only Tacrolimus vial-format solution for healthcare providers and transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results